

Pharmacy Prior Approval Request for Immunomodulators: Orencia

Beneficiary Information

Beneficiary Last Name:	2. First Name:	
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Beneficiary Gender:
Prescriber Information		
6. Prescribing Provider NPI #:		
		Phone #: Ext
Drug Information		
8. Drug Name:	9. Strength:	10. Quantity Per 30 Days:
11. Length of Therapy (in days): \Box	up to 30 Days \square 60 Days \square 90 Days \square 12	20 Days □ 180 Days □ 365 Days □ Other
Clinical Information		
2. Is the beneficiary not on ano 3. Has the beneficiary been con 4. Has the beneficiary been test 5. Has the beneficiary tried one leflunomide or sulfasalazine wit ☐ Yes ☐ No 6. Does the beneficiary have PJ 7. Has the beneficiary had a trial Humira? ☐ Yes ☐ No Request for Psoriatic arthritis 1. Does the beneficiary have a 6. Is the beneficiary 18 years of 3. Is the beneficiary not on ano 4. Has the beneficiary been confor Otezla)? ☐ Yes ☐ No 5. Has the beneficiary been test 6. Does the beneficiary have do	diagnosis of Polyarticular Juvenile Idiopather injectable biologic immunomodular sidered and screened for the presence are with Hep B SAG and Core Ab?	tor? Yes No of latent tuberculosis infection? Yes No us No ue, methylprednisolone) or methotrexate, take these therapies due to contraindications? Yes No inical reason beneficiary cannot try Enbrel or riatic Arthritis? Yes No of latent tuberculosis infection (not required

Fax this form to (833) 404-2393



Pharmacy Prior Approval Request for Immunomodulators: Orencia

Request for Rheumatoid arthritis							
1. Does the beneficiary have a diagnosis of Rheumatoid Arthritis? \square Yes \square No							
2. Is the beneficiary not on another injectable biologic immunomodulator? Yes No							
3. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? Yes No							
4. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No							
5. Does the beneficiary have a body surface area (BSA) involvement of at least 3%? Yes No							
6. Has the beneficiary experienced a therapeutic failure/inadequate response with methotrexate or at least one							
disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)?							
□ Yes □ No							
7. Is the beneficiary unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications	5						
or intolerability? Yes No							
8. Does the beneficiary have clinical evidence of severe or rapidly progressing disease? Yes No							
9. Has the beneficiary had a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try either							
Enbrel or Humira? ☐ Yes ☐ No							
Request for Prophylaxis of acute Graft versus Host Disease (aGVHD)							
1 Is the beneficiary undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-							
mismatched unrelated-donor? Yes No							
2. Is the beneficiary 2 years of age or older? ☐ Yes ☐ No							
3. Is the beneficiary taking in combination with a calcineurin inhibitor and methotrexate? ☐ Yes ☐ No 4. Is the beneficiary not on another injectable biologic immunomodulator? ☐ Yes ☐ No 5. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? ☐ Yes ☐ No							
				·			
				6. Has the beneficiary been tested with Hep B SAG and Core Ab? \square Yes \square No			
Signature of Prescriber: Date:							
(Prescriber Signature Mandatory)							

Fax this form to (833) 404-2393 Pharmacy PA Call Center: (833) 585-4309

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that

any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.